1[1]Orentreich N, Brind JL, Vogelman JH, et al. Long - term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men[J].J Clin Endocrinol Metab, 1992,75:1002.
2[2]Henry A,Feldman, Catherine B.et al. Low Dehydroepiandrosterone and Ischemic Heart Disease in Middle - aged Men: Prospective Results from the Massachusetts Male Aging Study[J] .American Journal of Epidemiology,2001,153(1): 79.
3[3]Trivedi DP,Khaw KT. Dehydroepiandrosterone Sulfate and Mortality in Elderly Men and Women[J] .The Journal of Clinical Endocrinology &Metabolism,2001,86( 9 ) :4171.
4[4]Barrett - Connor E, Goodman - Gruen D. The epidemiology of DHEAS and cardiovascular disease[J] .Ann N Y Acad Sci, 1995,774: 259.
5[5]Tilvis RS, Kahonen M, Harkonen M. Dehydroepiandrosterone sulfate diseases and mortality in a general aged population[J] .Aging (Milano),1999,11(1):30.
6[6]Kiechl S, Willeit J, Bonora E, et al. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study) [J]. Arterioscler Thromb Vasc Biol,2000,20(4): 1094.
7[7]Newcomer LM, Manson JE, Barberi RL et al. Dehydroandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study[J]. Am J Epidemiol, 1994,140: 870.
8[8]Jansson JH, Nilsson TK, Johnson O.Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predicts cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction [J ]. Heart, 1998,80: 334.
9[9]Hautanen A, Manttari M, Manninen V.Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study[J] .Atherosclerosis, 1994,105(2): 191.
10[10]Khaw KT. Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease[J] .J Endocrinol, 1996,150: 149.
